141 related articles for article (PubMed ID: 34586488)
1. MiR-519d-3p enhances the sensitivity of non-small-cell lung cancer to tyrosine kinase inhibitors.
Zhen Q; Zhang Y; Gao L; Wang R; Chu W; Zhao X; Li Z; Li H; Zhang B; Lv B; Liu J
Mamm Genome; 2021 Dec; 32(6):508-516. PubMed ID: 34586488
[TBL] [Abstract][Full Text] [Related]
2. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells.
Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z
Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212
[TBL] [Abstract][Full Text] [Related]
3. MiR-133a-3p attenuates resistance of non-small cell lung cancer cells to gefitinib by targeting SPAG5.
Li Q; Wang Y; He J
J Clin Lab Anal; 2021 Jul; 35(7):e23853. PubMed ID: 34057242
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
[TBL] [Abstract][Full Text] [Related]
5. miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
Gao Y; Fan X; Li W; Ping W; Deng Y; Fu X
Biochem Biophys Res Commun; 2014 Mar; 446(1):179-86. PubMed ID: 24582749
[TBL] [Abstract][Full Text] [Related]
6. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
Wang HY; Liu YN; Wu SG; Hsu CL; Chang TH; Tsai MF; Lin YT; Shih JY
Cancer Biomark; 2020; 28(3):351-363. PubMed ID: 32417760
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of N-Acetylglucosaminyltransferase GCNT3 by miR-302b-3p Decreases Non-Small Cell Lung Cancer (NSCLC) Cell Proliferation, Migration and Invasion.
Li Q; Ran P; Zhang X; Guo X; Yuan Y; Dong T; Zhu B; Zheng S; Xiao C
Cell Physiol Biochem; 2018; 50(3):987-1004. PubMed ID: 30355927
[TBL] [Abstract][Full Text] [Related]
8. Circ_0011292 knockdown mitigates progression and drug resistance in PTX-resistant non-small-cell lung cancer cells by regulating miR-433-3p/CHEK1 axis.
Jin M; Zhang F; Li Q; Xu R; Liu Y; Zhang Y
Thorac Cancer; 2022 May; 13(9):1276-1288. PubMed ID: 35348291
[TBL] [Abstract][Full Text] [Related]
9. miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
Ge P; Cao L; Chen X; Jing R; Yue W
BMC Cancer; 2019 Dec; 19(1):1203. PubMed ID: 31823748
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of miR-506-3p Facilitates EGFR-TKI Resistance through Induction of Sonic Hedgehog Signaling in Non-Small-Cell Lung Cancer Cell Lines.
Haque I; Kawsar HI; Motes H; Sharma M; Banerjee S; Banerjee SK; Godwin AK; Huang CH
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291316
[TBL] [Abstract][Full Text] [Related]
11. miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.
Baumgartner U; Berger F; Hashemi Gheinani A; Burgener SS; Monastyrskaya K; Vassella E
Mol Cancer; 2018 Feb; 17(1):44. PubMed ID: 29455644
[TBL] [Abstract][Full Text] [Related]
12. MiR-200c-3p and miR-485-5p overexpression elevates cisplatin sensitivity and suppresses the malignant phenotypes of non-small cell lung cancer cells through targeting RRM2.
Liu Y; Zhang Y; Li Q; Xu R; Huang N
Thorac Cancer; 2022 Jul; 13(13):1974-1985. PubMed ID: 35599447
[TBL] [Abstract][Full Text] [Related]
13. Long Noncoding RNA Regulator of Reprogramming Regulates Cell Growth, Metastasis, and Cisplatin Resistance in Gastric Cancer via miR-519d-3p/HMGA2 Axis.
Jin W; Zhang H; Li M; Lin S
Cancer Biother Radiopharm; 2023 Mar; 38(2):122-131. PubMed ID: 32614615
[No Abstract] [Full Text] [Related]
14. Downregulation of long non-coding RNA XIST inhibits cell proliferation, migration, invasion and EMT by regulating miR-212-3p/CBLL1 axis in non-small cell lung cancer cells.
Qiu HB; Yang K; Yu HY; Liu M
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8391-8402. PubMed ID: 31646569
[TBL] [Abstract][Full Text] [Related]
15. LncRNA NORAD, sponging miR-363-3p, promotes invasion and EMT by upregulating PEAK1 and activating the ERK signaling pathway in NSCLC cells.
Geng Q; Li Z; Li X; Wu Y; Chen N
J Bioenerg Biomembr; 2021 Jun; 53(3):321-332. PubMed ID: 33742335
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-330-3p promotes cell invasion and metastasis in non-small cell lung cancer through GRIA3 by activating MAPK/ERK signaling pathway.
Wei CH; Wu G; Cai Q; Gao XC; Tong F; Zhou R; Zhang RG; Dong JH; Hu Y; Dong XR
J Hematol Oncol; 2017 Jun; 10(1):125. PubMed ID: 28629431
[TBL] [Abstract][Full Text] [Related]
17. Endothelial PAS domain-containing protein 1 confers TKI-resistance by mediating EGFR and MET pathways in non-small cell lung cancer cells.
Zhen Q; Liu JF; Liu JB; Wang RF; Chu WW; Zhang YX; Tan GL; Zhao XJ; Lv BL
Cancer Biol Ther; 2015; 16(4):549-57. PubMed ID: 25831463
[TBL] [Abstract][Full Text] [Related]
18. LINC00839/miR-519d-3p/JMJD6 axis modulated cell viability, apoptosis, migration and invasiveness of lung cancer cells.
Yu X; Jiang Y; Hu X; Ge X
Folia Histochem Cytobiol; 2021; 59(4):271-281. PubMed ID: 34734406
[TBL] [Abstract][Full Text] [Related]
19. Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer.
Shen H; Zhu F; Liu J; Xu T; Pei D; Wang R; Qian Y; Li Q; Wang L; Shi Z; Zheng J; Chen Q; Jiang B; Shu Y
PLoS One; 2014; 9(7):e103305. PubMed ID: 25058005
[TBL] [Abstract][Full Text] [Related]
20. LncRNA NNT-AS1 promotes non-small cell lung cancer progression through regulating miR-22-3p/YAP1 axis.
He W; Zhang Y; Xia S
Thorac Cancer; 2020 Mar; 11(3):549-560. PubMed ID: 31923353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
